{"id":25236,"date":"2022-10-09T21:37:00","date_gmt":"2022-10-09T13:37:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25236"},"modified":"2025-02-03T21:41:42","modified_gmt":"2025-02-03T13:41:42","slug":"ark-biosciences-ziresovir-shows-positive-results-in-phase-iii-airflo-study-for-rsv-infection","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25236","title":{"rendered":"Ark Biosciences&#8217; Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection"},"content":{"rendered":"\n<p>China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its novel antiviral drug ziresovir (AK0529). The study evaluated the efficacy and safety of ziresovir in hospitalized infants with respiratory syncytial virus (RSV) infection. The drug achieved its primary endpoint of a significant reduction in symptom severity (S&amp;S) score compared to a placebo and also met the key secondary endpoint of viral load reduction.<\/p>\n\n\n\n<p><strong>Study Design and Results<\/strong><br>The randomized, double-blind, placebo-controlled, multi-center Phase III study assessed the drug in infants aged 1 to 24 months with moderate to severe RSV infection in China. Results showed that ziresovir demonstrated rapid clinical efficacy, with a 30% improvement in symptom scores compared to the placebo group on the third day of treatment. In the high-risk population of infants under six months old, ziresovir achieved a 55% improvement in symptom scores. Additionally, ziresovir significantly shortened intensive care unit (ICU) treatment time for patients with severe RSV-related diseases (3 days vs. 8 days).<\/p>\n\n\n\n<p><strong>Antiviral Efficacy and Safety Profile<\/strong><br>Ziresovir also exhibited significant antiviral effects, with a 77% reduction in viral load on the fifth day of treatment compared to the placebo group. Throughout the treatment period, viral load remained significantly lower in the ziresovir group. The AIRFLO study further confirmed the good safety and tolerability of ziresovir, with no significant difference in adverse event incidence between the ziresovir and placebo groups.<\/p>\n\n\n\n<p><strong>Global Significance and Regulatory Milestones<\/strong><br>Ziresovir is the world\u2019s first oral RSV drug to complete a Phase III pivotal study and the first home-grown pediatric drug being developed globally. The drug previously received breakthrough therapy designation (BTD) from China\u2019s National Medical Products Administration, highlighting its potential to address a significant unmet medical need in pediatric RSV infections.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1443,34,17,68],"class_list":["post-25236","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ark-biopharmaceutical","tag-breakthrough-therapy","tag-clinical-trial-results","tag-pediatric-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ark Biosciences&#039; Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its novel antiviral drug ziresovir (AK0529). The study evaluated the efficacy and safety of ziresovir in hospitalized infants with respiratory syncytial virus (RSV) infection. The drug achieved its primary endpoint of a significant reduction in symptom severity (S&amp;S) score compared to a placebo and also met the key secondary endpoint of viral load reduction.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25236\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ark Biosciences&#039; Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25236\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-09T13:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-03T13:41:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25236#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25236\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ark Biosciences&#8217; Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection\",\"datePublished\":\"2022-10-09T13:37:00+00:00\",\"dateModified\":\"2025-02-03T13:41:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25236\"},\"wordCount\":303,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ark Biopharmaceutical\",\"Breakthrough therapy\",\"Clinical trial results\",\"Pediatric drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25236#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25236\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25236\",\"name\":\"Ark Biosciences' Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-09T13:37:00+00:00\",\"dateModified\":\"2025-02-03T13:41:42+00:00\",\"description\":\"China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its novel antiviral drug ziresovir (AK0529). The study evaluated the efficacy and safety of ziresovir in hospitalized infants with respiratory syncytial virus (RSV) infection. The drug achieved its primary endpoint of a significant reduction in symptom severity (S&S) score compared to a placebo and also met the key secondary endpoint of viral load reduction.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25236#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25236\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25236#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ark Biosciences&#8217; Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ark Biosciences' Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection - Insight, China&#039;s Pharmaceutical Industry","description":"China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its novel antiviral drug ziresovir (AK0529). The study evaluated the efficacy and safety of ziresovir in hospitalized infants with respiratory syncytial virus (RSV) infection. The drug achieved its primary endpoint of a significant reduction in symptom severity (S&S) score compared to a placebo and also met the key secondary endpoint of viral load reduction.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25236","og_locale":"en_US","og_type":"article","og_title":"Ark Biosciences' Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25236","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-09T13:37:00+00:00","article_modified_time":"2025-02-03T13:41:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25236#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25236"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ark Biosciences&#8217; Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection","datePublished":"2022-10-09T13:37:00+00:00","dateModified":"2025-02-03T13:41:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25236"},"wordCount":303,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ark Biopharmaceutical","Breakthrough therapy","Clinical trial results","Pediatric drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25236#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25236","url":"https:\/\/flcube.com\/?p=25236","name":"Ark Biosciences' Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-09T13:37:00+00:00","dateModified":"2025-02-03T13:41:42+00:00","description":"China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its novel antiviral drug ziresovir (AK0529). The study evaluated the efficacy and safety of ziresovir in hospitalized infants with respiratory syncytial virus (RSV) infection. The drug achieved its primary endpoint of a significant reduction in symptom severity (S&S) score compared to a placebo and also met the key secondary endpoint of viral load reduction.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25236#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25236"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25236#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ark Biosciences&#8217; Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25236"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25236\/revisions"}],"predecessor-version":[{"id":25237,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25236\/revisions\/25237"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}